SWEDEN, - Oct 21, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders will attend a leading US dermatology conference, Fall Clinical, to further enhance the clinical adoption and market expansion of Nevisense. The Fall Clinical conference attracts more than 1,100 clinicians looking to bridge gaps within the detection and diagnosis of melanoma clinical pathway. The conference offers comprehensive workshops and sessions led by top dermatology experts highlighting the latest advances in the diagnoses and treatment of various conditions and diseases. Nevisense will be included in several sessions focused on integrating technology into the melanoma detection and diagnostic clinical pathway.
SciBase continues to expand geographically in the US with new practices added in Maryland, Colorado and as recently published Pennsylvania. The Fall Clinical conference will provide an opportunity to further extend the US footprint and provide new customers with Nevisense. Nevisense is today the only FDA approved, non-invasive option for the detection of melanoma at an early stage when the disease is highly curable.
The new consensus report that was published in the JDD (September 2024 issue) will also be presented at the 44th annual Fall Clinical Dermatology Conference (“Fall Clinical 2024”). The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care.
“It is very encouraging to see that our recently added resources already are expanding our geographical footprint in the US, and we have recently opened up new markets in Pennsylvania, Maryland and Colorado. We are excited to continue this momentum during the Fall Clinical 2024 conference. SciBase is proud to support and attend the Fall Clinical 2024 conference and we look forward to engaging with our current customers as well as establishing new customers to further our mission of providing both clinicians and patients with improved outcomes and to positively impact the betterment of patient care.,” said Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2025:
Anders Bladh (Ribbskottet AB),
Fredrik Mattsson (Ejendals AB)
Dharminder Chahal (VanHerk Group),
Jesper Høiland (Chairman of the Board).
The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on June 13, 2024.
The Annual General Meeting of SciBase Holding AB (publ) will be held on May 21, 2025 in Stockholm.
Shareholders who wish to have an item considered by the nominating committee can do this in writing to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm or by e-mail to [email protected] Att: Chairman of the Board (who is the convenor of the nominating committee).
Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to SciBase Holding AB (publ), Att: Chairman of the Board, Box 3337, 103 67 Stockholm, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.
Stockholm, October 14, 2024
SciBase Holding AB (publ)
For more information, please contact: Jesper Høiland, Chairman of the board, phone +45 612 207 30
Michael Colérus, CFO, phone +46 70 341 34 72
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase and Nevisense
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
SWEDEN, - Sept 27, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatologydisorders is pleased to announce the completion of a milestone sale of Nevisense, a leading skin barrier research device, to the National Institutes of Health (NIH), one of the world's foremost medical research centers and a part of the U.S. Department of Health and Human Services. This sale represents a major milestone for SciBase and demonstrates the high quality and innovative nature of Nevisense for research.
The device will be used to conduct research on the microbiome and its interactions in atopic dermatitis (AD), exploring how the microbiome may unearth new treatments for AD.
“The fact that this prestigious governmental institution has chosen to use Nevisense in their research speaks volumes about the credibility and reliability of our product” says Pia Renaudin, CEO of SciBase. “The skin barrier research market is experiencing a rapid rise in interest, and the research in this space can directly improve the lives of millions of people worldwide. We are confident that the use of our device by the NIH will lead to groundbreaking discoveries and advancements in the field of dermatology.”
Nevisense is, apart from being able to detect skin cancer, also designed to analyze skin barrier function with the highest accuracy and robustness available, making it an essential tool for researchers. To date, studies have included Nevisense to study skin disorders, investigate environmental irritants and their effect on skin health, and analyze skin barrier dysfunction as it relates to allergies.
For more information on Nevisense for research and SciBase's medical products, visit www.scibase.com or contact Jeremy Bost at [email protected] .
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
SWEDEN, - Sept 26, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces today a partnership with Seraly Dermatology in Pittsburgh, Pennsylvania. The strategic collaboration will allow SciBase to continue to broaden access of the Nevisense test to patients across the US, and further their commitment to the early detection of melanoma, when the disease is almost 100% curable. Seraly Dermatology will integrate several Nevisense systems into their skin cancer detection workflow.
“Melanoma is the deadliest form of skin cancer and catching it early is key to survival. At Seraly Dermatology, we believe in providing our patients with the most advanced personalized care. For these reasons, we are keen to integrate the Nevisense test into our melanoma detection workflow. The Nevisense technology non-invasively analyzes the cellular structure of a patient’s atypical moles right at point of care. This can help us not only personalize that patient’s care but also improve clinical outcomes by practicing the earliest melanoma detection possible” says Mark Seraly, MD, Board-Certified Dermatologist, founder and CEO of Seraly Dermatology.
”We are thrilled to commence a partnership with Seraly Dermatology Their focus on individual patient care is one of many reasons we are proud to partner with them. I’m also pleased to see that our recent U.S. team expansion is already having a positive impact on the U.S. market by increasing access of the Nevisense test to more patients in new geographic areas”, says Pia Renaudin, CEO of SciBase.
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing on early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reportsvisit: http://investors.scibase.se/en/pressreleases
Consensus reached by top US clinicians assessing technologies for melanoma detection and management
The report concludes that the Nevisense AI-driven technology can significantly enhance early melanoma detection
SWEDEN, - Sept 02, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], pioneering prevention and prediction in dermatology announces that key US clinicians and scientists reached consensus on Nevisense and how it can significantly enhance the diagnostic assessment and clinical decision-making for early melanoma at point of care. Nevisense is an AI-driven, non-invasive technology, and the only FDA-approved device for early skin cancer detection.
The consensus report evaluated several technologies for melanoma diagnosis and supports the use of Nevisense for its ability to significantly enhance clinician’s diagnostic assessment of atypical moles by non-invasively providing them with critical information at point of care. The report was published in the Journal of Drugs in Dermatology (JDD) – a peer-reviewed, dermatology journal. The report co-authors included top US clinicians such as Seemal R. Desai, MD, Keyvan Nouri, MD, Aaron S. Farberg, MD, Gary Goldenberg, MD, Mark Lebwohl, MD, and Darrell Rigel, MD, MS, Brian Berman, MD, PhD, Brad Glick, DO, MPH, Mark Nestor, MD, PhD, MBA, and Theodore Rosen, MD.
“I am so excited that this renowned panel of leading dermatologists has endorsed Nevisense as an important tool for early detection of melanoma. This is a significant step forward for SciBase in our US commercialization process” says Pia Renaudin, CEO of SciBase.
” Melanoma is one of the top 5 most common cancers in the US and is the main cause of skin cancer deaths in the United States. Early detection is critical to survival and one of the few ways to improve clinical outcomes for patients. With melanoma, timing and the earliest detection possible can make a significant positive impact on survival rates and outcomes. For these reasons, we as clinicians can provide our patients with AI-powered Nevisense, which is an advanced technology that enhances early detection while easily integrating at the point-of-care”, said Dr. Darrell Rigel, board-certified dermatologist, Clinical Professor of Dermatology Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, Adjunct Professor, UT Southwestern Medical School, Consultant Dermatologist, Cooper Clinic. Dr. Rigel served as President of the American Academy of Dermatology, the American Academy of Dermatology Association, the American Society for Dermatologic Surgery and the American Dermatological Association, as a Director of the American Board of Dermatology, and is the current Chair of SkinPAC (the American Academy of Dermatology Association’s political action committee).
"Nevisense is a powerful combination of human intelligence and artificial intelligence working together to improve clinical outcomes. At Goldenberg Dermatology, we strive to provide our patients with the highest standard of care with the most advanced technology. Nevisense helps clinicians identify more atypical pigmented skin lesions, which in turn helps increase detection rates. The clinically proven and validated science, and ease of practical integration were all key to reaching consensus", said Dr. Gary Goldenberg, board certified dermatologist and dermatopathologist, CEO and founder of Goldenberg Dermatology PC, and Assistant Clinical Professor of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York City.
The article can be found here : https://jddonline.com/articles/advances-in-technology-melanoma-diagnosis-prognosis-an-expert-consensus-panel-S1545961624P8365X/
For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company’s Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SWEDEN, 21 August 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin, hereby announces change of Certified Adviser from Vator Securities to Carnegie Investment Bank AB (publ).
SciBase has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the position as Certified Adviser. Carnegie Investment Bank AB (publ) will assume the role of Certified Adviser effective from September 1, 2024. Until then, Vator Securities will continue to act as the Certified Adviser for the company.
For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
The cash flow from current operations was negative in the amount of TSEK 15,179 (13,054).
The gross margin was 69.1% (65.3%).
Electrode sales volume increased by 24% and was 14,106 (11,330) units. Repeat sales of electrodes to existing customers increased by 22%.
January - June in figures
Net sales were TSEK 12,699 (10,234), +24%.
The loss after tax was TSEK 25,911 (22,258).
The loss per share was SEK 0.19 (0.31).
The cash flow from current operations was negative in the amount of TSEK 28,360 (16,805).
The gross margin was 69.5% (67.0%).
Electrode sales volume increased by 21% and was 27,868 (22,944) units. Repeat sales of electrodes to existing customers increased by 23%.
Important events during the quarter
Overall sales increased by 31% (+30, before currency effects). Sales in Germany within the skin cancer segment increased by 12%(11% in local currency). Sales in the US skin cancer market increased by 468% while the sales within the skin barrier segment increased by 7%.
SciBase resolved on a directed issued of approximately SEK 33 million and a rights issue of approximately SEK 15 million and postponed the Annual General Meeting and publication of the interim report for the first quarter of 2024.
SciBase published a prospectus and the summons to an EGM and the AGM.
SciBase announced a new partnership with Al Shirawi Healthcare solutions for the distribution of Nevisense in the UAE.
SciBase published the outcomes in the directed issue, were MSEK 33 were subscribed for and in the rights offering were MSEK were subscribed for corresponding to a subscription rate of 61%.
New German study shows Nevisense significantly improves dermatologists’ clinical decisions.
SciBase launched the eBarrier Score, the First AI-Driven Skin Barrier Assessment tool for research and Cosmetic Testing.
SciBase received the first order in Austria.
US organization strengthened with experienced leader in dermatology.
Partnership established with a large health care group in Los Angeles, Unified Health, and SciBase receives a first order.
The AGM was held on June 13th, new chairman of the Board appointed.
Important events after the end of the period
No events of significant nature have occurred after the end of the period.
Financial overview
July 1, 2023 -
Apr 1 - June 30
Jan 1 - June 30
June 30, 2024
Jan 1 - Dec 31
THE GROUP
2024
2023
2024
2023
Rolling-12
2023
Net sales, SEK ths
6 641
5 085
12 699
10 234
25 710
23 245
Gross margin, %
69.1%
65.3%
69.5%
67.0%
70.0%
69.0%
Equity/Asset ratio, %
71.8%
73.7%
71.8%
73.7%
72.9%
66.9%
Net indebtness, multiple
0.39
0.36
0.39
0.36
0.37
0.49
Cash equivalents, SEK ths
43 271
70 874
43 271
70 874
43 271
34 121
Cashflow from operating activities, SEK ths
-15 179
-13 054
-28 360
-16 805
-63 539
-51 984
Earnings per share (before and after dilution), SEK
-0.08
-0.16
-0.19
-0.31
-0.46
-0.51
Shareholder's equity per share, SEK
0.28
0.60
0.39
0.75
0.49
0.40
Average number of shares, 000'
186 303
119 831
136 449
96 129
128 140
107 980
Number of shares at closing of period, 000'*
219 538
119 831
219 538
119 831
219 538
119 831
Share price at end of period, SEK
0.51
1.19
0.51
1.19
0.51
0.83
Number of sold electrodes, pieces
14 016
11 330
27 868
22 944
56 844
51 920
Average number of employees
27
22
27
21
26
23
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on August 21, 2024.
This interim report report has not been subject to review by the Company’s auditors
Contact person:
Michael Colérus, CFO, +46 70 341 34 72
For more information, please contact: Pia Renaudin, CEO SciBase Tel: +46 73 206 98 02 Email: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SVERIGE, 28 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase], a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.
"At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality of dermatological care to our patients, especially when it comes to the earliest detection possible of melanoma - the deadliest form of skin cancer. For these reasons, we are excited to use Nevisense and believe it will help us improve outcomes for our patients", says Michael Lin, MD, Board-Certified Dermatologist and Founder of Unified Health.
"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes", says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable".
For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election of Jesper Høiland as the new Chairman of the Board.
We are pleased to announce the election of Jesper Høiland as the new Chairman of the Board. Jesper has over 25 years of experience from senior positions in global pharmaceutical companies such as Ascendis Pharma (CCO), Radius Health (CEO) and Novo Nordisk (President and EVP for the US with a particular focus on pricing, product launches and infrastructure building). Jesper has lived and worked in the US, Switzerland, Denmark, Australia, France, Belgium and Canada for the past 30 years.
"We are happy about the election of Jesper Høiland as the new Chairman of our board," says Pia Renaudin CEO of SciBase. "He will bring valuable insights and experience especially from the US market, which is our primary focus. We also welcome, as previously communicated, Robert Molander as new member of the Board. "
In addition, we would like to extend our gratitude to Tord Lendau for his commitment and invaluable contributions during his lead as Chairman of the Board. Tord has been a member of the board since 2014. During this time SciBase has made significant progress in navigating challenging regulatory processes and market environments and has reached profitability in Germany through growing sales of Nevisense and electrodes. Nevisense remains the only melanoma detection product approved in the US. The foundation for further growth has been laid.
"We extend our deepest thanks to Tord for his exceptional leadership and commitment to SciBase," says Pia Renaudin. "He has been instrumental in SciBase progress. I also want to take the opportunity to thank both Dr Matt Leavitt and Jvalini Dwarkasing for their support in driving SciBase forward as they now retire as members of the Board. "
SciBase is excited about the future and remains committed to become the standard of Care in the areas we work in. We look forward to achieving new milestones and providing our AI driven technology to clinicians so they can improve and save lives through timely detection and intervention at the first signs of skin diseases and to reduce healthcare costs.
For additional information, please contact: Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases
Today, the annual general meeting of 2024 was held in SciBase Holding AB (publ) (the "Company" or "SciBase"). Below follows a summary of the resolutions passed at the annual general meeting, which included the election of Jesper Høiland and Robert Molander as new members of the board of directors and the election of Jesper Høiland as new chairman of the board of directors.
The annual general meeting resolved:
to adopt the profit and loss statement and the balance sheet and the group profit and loss statement and the group balance sheet for the financial year 2023;
that SEK 202,523,429 shall be carried forward in new account and that no dividend shall be paid;
to grant the board members and the CEOs discharge from liability for the financial year 2023;
that the board of directors shall consist of four ordinary members without deputy members and that a registered accounting firm shall be elected as auditor;
that the fees payable to the board of directors for the period until the end of the next annual general meeting shall be SEK 404,000 for the chairman of the board and SEK 135,000 to each of the other ordinary board members (who are not employed by a larger shareholder in the Company), as proposed by the Company's major shareholder, and that fees payable to the auditor is to be paid in accordance with approved invoices;
for the period until the end of the next annual general meeting, to re-elect Diana Ferro and Thomas Taapken as board members and to elect Jesper Høiland and Robert Molander as new board members, to elect Jesper Høiland as new chairman of the board of directors and to re-elect the auditing firm PricewaterhouseCoopers AB (PwC) as auditor for the Company, with Magnus Lagerberg as auditor-in-charge;
to adopt principles for the appointment of a nomination committee (same principles as previous year); and
to authorize the board of directors to increase the share capital through issuance of new shares, warrants and/or convertible debentures. Through issuances resolved upon with support from the authorisation - with deviation from the shareholders' preferential rights - the number of shares issued, or number of shares created in connection with exercise of warrants or conversion of convertibles, shall correspond to not more than a 20 per cent dilution of the share capital and the number of shares and votes in the Company after such issue(s).
Information regarding the newly elected board members' education, experience, assignments and independence can be found on the Company's website https://investors.scibase.se/en/governance/annual-general-meeting.
For more information, please contact: Pia Renaudin, CEO SciBase
Tel: +46 73 206 98 02
Email: [email protected]
The information was submitted, through the agency of the contact person set out above, for publication at the time stated by Scibase's news distributor Cision upon publication of this press release.
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases .
